Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background The licensed anesthetic xenon, which exerts organ protective properties, was recently added by the World Anti-Doping Agency to the list of prohibited substances. Xenon is supposed to trigger the production of hypoxia-inducible factor 1α (HIF-1α) and subsequently erythropoietin, but data are limited to in vivo experimental work. Therefore we evaluated the effect of xenon on erythropoietin levels in healthy persons.Methods Twenty-four healthy volunteers were randomly assigned either to a group spontaneously breathing xenon 30 % (Xe/O 2 30 %/60 %) or a group breathing control gas (N 2/O 2 40 %/60 %) for 45 min. Primary outcome parameters were erythropoietin levels at several time-points after exposure. Secondary outcome parameters were serum levels of testosterone, cytokines, and growth factors as well as concentrations of xenon in blood and exhalation samples measured at several time-points after exposure. In addition, hemodynamic safety parameters were monitored during exposure.Results The administration of xenon significantly increased erythropoietin levels 8 h after exposure (1.34 [±0.368]; p = 0.008), peaking at 24 h compared to the baseline values (1.45 [±0.498]; p = 0.01) and remained traceable in blood and exhalation probes until 24 h after exposure. In contrast, no significant change was observed in the control group. Measurement of stromal cell-derived factor 1 (SDF-1) revealed a significant increase of SDF-1 levels (p = 0.005), whereas no differences were observed with respect to growth factors, cytokines, or androgens. In an in vitro chemotaxis assay, endothelial progenitor cells (EPCs) showed a trend towards increased migration in serum samples received from participants after xenon exposure (p = 0.080).Conclusion The present study presents first evidence about a xenon-induced effect on increased erythropoietin levels in healthy volunteers. The study was registered at the European Medicines Agency (EudraCT-number: 2014-000973-38) and at ClinicalTrials.gov (NCT number: 02129400).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study from 2016, Stoppe et al. concluded that xenon indeed increases erythropoietin levels in healthy volunteers (58).”
From The Inclusion in WADA Prohibited List Is Not Always Supported by Scientific Evidence: A Narrative Review (2021) · cites this paper as [58]
Citations
Cites
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645 · cited 2×
“Alternatively xenon was demonstrated to induce the activation of Erk1/2 [28], which, in turn, is known to increase the expression of HIF-1a [29, 30].”
BackgroundProgenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600 · cited 9×
“4a, b), circulating serum levels of SDF-1 were significantly higher in the xenon group at 4 and 8 h after exposure (Fig.”
BackgroundResultInfluentialRegulation of erythropoietin production
Jelkmann, W. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.195057 · Cited by 599
Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators
Déry, M.-A. C., Michaud, M. D., & Richard, D. E. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.08.012 · Cited by 545 · cited 2×
“Xenon preconditioning induces the stabilization and expression of HIF-1a and its downstream effector EPO via the PI3K-mTOR-p70S65 pathway [12, 27].”
BackgroundNew Avenues of Exploration for Erythropoietin
Maiese, K. (2005) · JAMA · doi:10.1001/jama.293.1.90 · Cited by 528 · cited 3×
“Considering the beneficial effects of EPO, we consider that these mainly derive from its well-characterized cytoprotective properties and pleiotropic effects on the brain, kidney, and cardiovascular system [7], which may significantly increase the functional capacity in the different organ systems.”
BackgroundMACDOUGALL, I. C., GRAY, S. J., ELSTON, O., BREEN, C., JENKINS, B., BROWNE, J., & EGRIE, J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10112392 · Cited by 433
Chong, Z. Z., Kang, J.-Q., & Maiese, K. (2002) · Circulation · doi:10.1161/01.cir.0000039103.58920.1f · Cited by 381 · cited 1×
“Beside its stimulating effect on erythropoiesis, EPO is thought to activate various cardioprotective pathways including phosphatidylinositol 3-kinase (PI3K), activated protein kinase B (PKB/Akt), Janus kinase and signal transducers and activators of transcription (JAK-STAT), and glycogen synthase kinase 3b (GSK-3b), r…”
BackgroundTargeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
Eltzschig, H. K., Bratton, D. L., & Colgan, S. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4422 · Cited by 366
Preconditioning and postconditioning: United at reperfusion
Hausenloy, D. J., & Yellon, D. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.06.005 · Cited by 285
Najjar, S. S. (2011) · JAMA · doi:10.1001/jama.2011.592 · Cited by 218 · cited 1×
“after restoration of myocardial blood flow [9, 36, 37].”
Research works printed but not linked: 2
- Bukhtiyarov IV, Kalmanov AS, Kislyakov UU, Nikiforov DA, Chistov SD, Shvetskiy FM, Bubeyev UA. Studying of xenon adaptility within training process for functional state correction in sportsmen. НАУЧНО&ПРАКТИЧЕСКИЙ ЖУРНАЛ. 2010;6 (78):22.
- Kalmanov AS, Yu A, Bubeev, Kotrovskaya TI. Course application effect of oxygen-xenon gas mixture inhalation on functional status of mountaineers. НАУЧНО&ПРАКТИЧЕСКИЙ ЖУРНАЛ. 2011;3(87):28.
Cited by
Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects
Heuberger, J. A. A. C., & Cohen, A. F. (2019) · Sports Medicine · doi:10.1007/s40279-018-1014-1 · Cited by 108
Neuroprotective Properties of Xenon
Maze, M., & Laitio, T. T. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01761-z · Cited by 66
Campos-Pires, R., Onggradito, H., Ujvári, E., Karimi, S., Valeo, F., Aldhoun, J. A., Edge, C. J., Franks, N. P., & Dickinson, R. (2020) · Critical Care · doi:10.1186/s13054-020-03373-9 · Cited by 50
“Xenon is a pleiotropic drug with actions at a variety of targets implicated in the secondary injury cascade, including NMDA receptors [6–8], potassium channels [9, 10], activation of HIF-1 alpha [11], and an increase in erythropoietin levels [12].”
BackgroundMaiese, K. (2016) · Current Neurovascular Research · doi:10.2174/1567202613666160729164900 · Cited by 37
Update of the organoprotective properties of xenon and argon: from bench to beside
Roehl, A. B., Rossaint, R., & Coburn, M. (2020) · Intensive Care Medicine Experimental · doi:10.1186/s40635-020-0294-6 · Cited by 41
Self-citation
Metadata
- Authors
- Stoppe, C., Ney, J., Brenke, M., Goetzenich, A., Emontzpohl, C., Schälte, G., Grottke, O., Moeller, M., Rossaint, R., & Coburn, M.
- Affiliations
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Stoppe, Christian
- ORCID
- Venue
- Sports Medicine
- Published
- 2016-03-03
- Volume
- 46
- Issue
- 11
- Pages
- 1753-1766
- ISSN
- 0112-1642 (ISSN-L)
- 1179-2035
- OpenAlex
- W2290858790
- Cited by
- 31
- References
- 44
- Citations by year
- 2025: 4 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 3 · 2016: 6
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-11-17)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Sports Medicine (publishedVersion)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Department of Anesthesiology, RWTH Aachen, Germany
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Physiology (medical) › Biomedical and Chemical Research
- Health Sciences › Medicine › Physiology (medical) › High Altitude and Hypoxia
- Keywords
- xenon, erythropoietin, hypoxia-inducible factor-1α, anti-doping, prohibited substances, CXCL12, endothelial progenitor cells, chemotaxis, testosterone, cytokines, growth factors, exhalation
- MeSH terms
- Doping in Sports, Erythropoietin, Humans, Xenon, Anesthetics, Inhalation, Chemokine CXCL12
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1007/s40279-016-0505-1
- The paper
- Stoppe, C., Ney, J., Brenke, M., Goetzenich, A., Emontzpohl, C., Schälte, G., Grottke, O., Moeller, M., Rossaint, R., & Coburn, M. (2016). Sub-anesthetic Xenon Increases Erythropoietin Levels in Humans: A Randomized Controlled Trial. Sports Medicine. https://doi.org/10.1007/s40279-016-0505-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.